Autism - 2014 Lancet review

What is autism?

Autism is a set of heterogeneous neurodevelopmental conditions, characterised by:

- early-onset difficulties in social communication
- unusually restricted, repetitive behavior and interests

How common is autism?

The worldwide population prevalence is 1%. Autism affects more males than females. Comorbidity is common (more than 70% have concurrent conditions).

Individuals with autism have atypical cognitive profiles:

- impaired social cognition, social perception, and executive dysfunction
- atypical perceptual and information processing

These profiles are underpinned by atypical neural development at the systems level.

Is it hereditary?

Genetics has a key role in the etiology of autism, in conjunction with developmentally early environmental factors. Large-effect rare mutations and small-effect common variants contribute to risk.

What is the treatment?

Early detection is essential for early intervention. Early comprehensive and targeted behavioral interventions can improve social communication and reduce anxiety and aggression.

Drugs can reduce comorbid symptoms, but do not directly improve social communication. Creation of a supportive environment that accepts and respects that the individual is different is crucial.

References:

Autism - The Lancet http://bit.ly/1h1TpyN


Cerebral palsy - 2014 Lancet review

Cerebral palsy encompasses a large group of childhood movement and posture disorders.

Overall prevalence has remained stable in the past 40 years at 2—3.5 cases per 1000 livebirths, despite improvements in antenatal and perinatal care.

Cerebral palsy is a lifelong disorder.

References:

Cerebral palsy - The Lancet http://bit.ly/1h1SXR4


Adenotonsillectomy for Childhood Sleep Apnea does not improve attention or executive function

Adenotonsillectomy for Childhood Sleep Apnea does not improve attention or executive function.

However, as compared with the watchful-waiting group, the early-adenotonsillectomy group had significant improvement on polysomnographic, behavioral, symptomatic, and quality-of-life measures.

However, 46% of the patients in the watchful-waiting group had a normalization of polysomnographic findings after 7 months

References:

NEJM article: http://buff.ly/167Vndb and editorial: http://bit.ly/14xa1WZ


Things Summer Camps Won't Tell You

From WSJ and MarketWatch:

10 things sleepaway camps won’t say - 10 things - MarketWatch http://on.mktw.net/11STOcg

Things Summer Camps Won't Tell You:


Related Posts with Thumbnails